Corbus Pharmaceuticals Holdings Inc CRBP

US Biotechnology

$7.14 ▼ -4.16% ($-0.31)

⬇️ Below Yest. Low 🎢 High Beta

Open $7.50

Prev Close $7.45

Day Range $6.97 – $7.59

52W Range $6.33 – $20.56

Market Cap $138.10M

Beta 2.74

EPS (TTM) $-6.17

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-10-24
Shares Out.	18,530,000
Website	corbuspharma.com/ ↗
Phone	16179630103
Employees	36
Revenue	$0
Gross Profit	$0
Net Income	-$35.0M
Free Cash Flow	-$86.7M
Total Assets	$127.0M
Total Liabilities	$24.7M
Equity	$102.2M

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Inc is a publicly traded company under the ticker symbol CRBP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.